\n<\/p>\n
“As a Federal Lawsuit Challenges the CMS Cannabinoid Program, Questions Mount Over Safety Standards, Scientific Validation, and Patient Protections” stated Duane Boise CEO MMJ International Holdings.<\/strong><\/i><\/p>\n<\/p><\/div>\n In March 2026, the European Food Safety Authority (EFSA)<\/strong> issued a formal scientific <\/a>rejection of Charlottes Web hemp product submission<\/a> concluding that the safety of a carbon dioxide extract derived from Cannabis sativa L.<\/i> – including products associated with leading U.S. brands – “cannot be established.”<\/strong><\/p>\n That conclusion was not based on politics. It was based on data.<\/strong><\/p>\n According to EFSA, critical gaps included:<\/p>\n Significant portions of the product remaining uncharacterized<\/strong><\/p>\n<\/li>\n Lack of reliable toxicological studies on the actual material<\/strong><\/p>\n<\/li>\n Absence of human clinical data<\/strong><\/p>\n<\/li>\n Unknown allergenicity and long-term safety profile<\/strong><\/p>\n<\/li>\n<\/ul>\n The agency’s bottom line was clear:<\/p>\n The safety of the product could not be determined.<\/strong><\/p>\n<\/blockquote>\n Meanwhile in the United States<\/strong><\/p>\n At nearly the same time, the Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive (BEI)<\/strong> program.<\/p>\n The initiative allows participating healthcare providers to discuss and furnish certain hemp, marijuana derived cannabinoid products<\/strong> to Medicare beneficiaries under Innovation Center authority.<\/p>\n Unlike traditional drug pathways, the BEI program does not require approval from the<\/strong> U.S. Food and Drug Administration.<\/p>\n That distinction is central to a federal lawsuit now pending:<\/p>\n Smart Approaches to Marijuana (SAM), et al. v. Robert F. Kennedy Jr., et al.<\/strong> The Scientific Gap<\/strong><\/p>\n Under the FDA framework, products intended for therapeutic use typically undergo:<\/p>\n Controlled clinical trials<\/p>\n<\/li>\n Dose standardization<\/p>\n<\/li>\n Safety and toxicology evaluation<\/p>\n<\/li>\n Manufacturing and stability validation<\/p>\n<\/li>\n<\/ul>\n The BEI program operates outside that structure.<\/p>\n While CMS has described the initiative as an innovation model<\/strong>, critics argue it effectively introduces products into federally funded care environments before those scientific benchmarks are met<\/strong>.<\/p>\n Why This Matters for Seniors<\/strong><\/p>\n Medicare beneficiaries represent one of the most medically complex populations in the healthcare system.<\/p>\n Many patients:<\/p>\n Cannabinoid compounds, including THC, are known to interact with metabolic pathways such as CYP450 enzymes<\/strong>, which are involved in processing many common medications.<\/p>\n Without controlled studies in this population, the full safety profile remains uncertain.<\/p>\n Rapid Supply Chain Expansion<\/strong><\/p>\n At the same time the program launched, several companies publicly announced positioning within the emerging healthcare supply chain:<\/p>\n Charlotte’s Web highlighted alignment with CMS guidance<\/p>\n<\/li>\n Cornbread Hemp announced institutional distribution through a national group purchasing organization<\/p>\n<\/li>\n<\/ul>\n These developments signal rapid commercialization of a category that has not undergone FDA drug approval review<\/strong>.<\/p>\n A Regulatory Tension<\/strong><\/p>\n The situation creates a notable contradiction:<\/p>\n International regulators say safety cannot be established<\/p>\n<\/li>\n The FDA has not approved these products as medicines<\/p>\n<\/li>\n Yet a federal healthcare program is enabling access within Medicare-linked systems<\/p>\n<\/li>\n<\/ul>\n That tension is now at the center of federal litigation.<\/p>\n What the Court Will Decide<\/strong><\/p>\n In SAM v. Kennedy (1:26-cv-01081)<\/strong>, the court is evaluating whether CMS exceeded its statutory authority by introducing cannabinoid furnishing pathways without:<\/p>\n A ruling is expected to determine whether the program:<\/p>\n The Core Question<\/strong><\/p>\n This debate ultimately comes down to a fundamental issue in healthcare policy:<\/p>\n Should access to therapeutic products come before scientific validation-<\/strong> Closing Perspective<\/strong><\/p>\n The EFSA conclusion does not ban CBD products.<\/p>\n But it does highlight a critical reality:<\/p>\n The scientific evidence needed to establish safety is still incomplete.<\/strong><\/p>\n As federal policy evolves, the question is not whether innovation should occur-<\/p>\n but whether it should occur before the science is fully understood<\/strong>, CONTACT:<\/strong><\/p>\n Madison Hisey
\n WASHINGTON, DC, May 8, 2026 (Newswire.com)
\n –
\n <\/strong>A growing conflict between international scientific findings and U.S. healthcare policy is raising urgent questions about whether Medicare beneficiaries are being exposed to cannabinoid products that have not been proven safe.<\/p>\n\n
\n
Case No. 1:26-cv-01081 (U.S. District Court for the District of Columbia)<\/strong><\/p>\n\n
\n
\n
or should science remain the gatekeeper?<\/strong><\/p>\n
particularly for the nation’s most vulnerable patients.<\/p>\n
MHisey@mmjih.com<\/a>
203-231-8583<\/p>\n